The stock of Vanda Pharmaceuticals Inc (VNDA) has gone up by 6.69% for the week, with a 16.59% rise in the past month and a -2.43% drop in the past quarter. The volatility ratio for the week is 4.66%, and the volatility levels for the past 30 days are 4.72% for VNDA. The simple moving average for the past 20 days is 8.42% for VNDA’s stock, with a -0.69% simple moving average for the past 200 days.
Is It Worth Investing in Vanda Pharmaceuticals Inc (NASDAQ: VNDA) Right Now?
Additionally, the 36-month beta value for VNDA is 0.72. There are mixed opinions on the stock, with 1 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
The public float for VNDA is 54.24M and currently, short sellers hold a 6.86% ratio of that float. The average trading volume of VNDA on March 05, 2025 was 666.01K shares.
VNDA) stock’s latest price update
Vanda Pharmaceuticals Inc (NASDAQ: VNDA)’s stock price has soared by 4.47 in relation to previous closing price of 4.81. Nevertheless, the company has seen a gain of 6.69% in its stock price over the last five trading days. prnewswire.com reported 2025-02-24 that WASHINGTON, Feb. 24, 2025 /PRNewswire/ — Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced the publication of an article entitled “Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S” in Molecular Therapy Nucleic Acids1, a Cell Press partner journal, that describes the development of a novel antisense oligonucleotide (ASO) therapeutic, VCA-894A, for a patient with a rare variant in the IGHMBP2 gene causing Charcot-Marie-Tooth disease Type 2S (CMT2S). In 1886, Jean-Martin Charcot, Pierre Marie, and Henry Tooth independently described this hereditary motor and sensory neuropathy in their patients, paving the way for Charcot-Marie-Tooth (CMT) disease research.2,3 It was not until 1968 that a distinction was made in CMT disease, creating the classification of CMT1 and CMT2.4 Since then, CMT disease (OMIM: 616155) has been used as a model disease to describe genetic heterogeneity.5 However, the high genetic and allelic heterogeneity of CMT disease poses a challenge for both diagnosis and treatment.
Analysts’ Opinion of VNDA
Many brokerage firms have already submitted their reports for VNDA stocks, with H.C. Wainwright repeating the rating for VNDA by listing it as a “Buy.” The predicted price for VNDA in the upcoming period, according to H.C. Wainwright is $18 based on the research report published on October 31, 2024 of the previous year 2024.
Cantor Fitzgerald, on the other hand, stated in their research note that they expect to see VNDA reach a price target of $11. The rating they have provided for VNDA stocks is “Overweight” according to the report published on July 11th, 2024.
Jefferies gave a rating of “Hold” to VNDA, setting the target price at $12 in the report published on February 25th of the previous year.
VNDA Trading at 9.05% from the 50-Day Moving Average
After a stumble in the market that brought VNDA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -25.56% of loss for the given period.
Volatility was left at 4.72%, however, over the last 30 days, the volatility rate increased by 4.66%, as shares surge +12.95% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +11.21% upper at present.
During the last 5 trading sessions, VNDA rose by +7.43%, which changed the moving average for the period of 200-days by -5.60% in comparison to the 20-day moving average, which settled at $4.64. In addition, Vanda Pharmaceuticals Inc saw 4.91% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VNDA starting from Polymeropoulos Mihael Hristos, who purchase 10,000 shares at the price of $4.71 back on Mar 03 ’25. After this action, Polymeropoulos Mihael Hristos now owns 2,275,731 shares of Vanda Pharmaceuticals Inc, valued at $47,050 using the latest closing price.
Polymeropoulos Mihael Hristos, the President and CEO of Vanda Pharmaceuticals Inc, purchase 10,000 shares at $4.76 during a trade that took place back on Feb 28 ’25, which means that Polymeropoulos Mihael Hristos is holding 2,361,730 shares at $47,600 based on the most recent closing price.
Stock Fundamentals for VNDA
Current profitability levels for the company are sitting at:
- -0.2 for the present operating margin
- 0.92 for the gross margin
The net margin for Vanda Pharmaceuticals Inc stands at -0.1. The total capital return value is set at -0.07. Equity return is now at value -3.49, with -2.90 for asset returns.
Based on Vanda Pharmaceuticals Inc (VNDA), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -1.27.
Currently, EBITDA for the company is -40.66 million with net debt to EBITDA at 2.77. When we switch over and look at the enterprise to sales, we see a ratio of 1.02. The receivables turnover for the company is 4.22for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.39.
Conclusion
In conclusion, Vanda Pharmaceuticals Inc (VNDA) has seen better performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
